Anixa Biosciences wins Australian patent for breast cancer vaccine through 2040 - ANIX News | RalliesAnixa Biosciences wins Australian patent for breast cancer vaccine through 2040
A
ANIX• Australian patent extends vaccine exclusivity
- Anixa Biosciences won its first Australian patent covering its breast cancer vaccine technology, extending exclusivity in Australia through 2040.
- The issued composition-of-matter patent covers vaccine adjuvants and formulations licensed from Cleveland Clinic.
- Anixa cited Phase 1 data showing the vaccine was safe, well tolerated, and triggered immune responses in more than 74% of participants.
MPB
•
